nach oben

Erschienen in:

Open Access 01.12.2020 | Research article

Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase

verfasst von: Katerina Hlozkova, Alena Pecinova, Natividad Alquezar-Artieda, David Pajuelo-Reguera, Marketa Simcikova, Lenka Hovorkova, Katerina Rejlova, Marketa Zaliova, Tomas Mracek, Alexandra Kolenova, Jan Stary, Jan Trka, Julia Starkova

Erschienen in: BMC Cancer | Ausgabe 1/2020

Abstract

Background

Effectiveness of L-asparaginase administration in acute lymphoblastic leukemia treatment is mirrored in the overall outcome of patients. Generally, leukemia patients differ in their sensitivity to L-asparaginase; however, the mechanism underlying their inter-individual differences is still not fully understood. We have previously shown that L-asparaginase rewires the biosynthetic and bioenergetic pathways of leukemia cells to activate both anti-leukemic and pro-survival processes. Herein, we investigated the relationship between the metabolic profile of leukemia cells and their sensitivity to currently used cytostatic drugs.

Methods

Altogether, 19 leukemia cell lines, primary leukemia cells from 26 patients and 2 healthy controls were used. Glycolytic function and mitochondrial respiration were measured using Seahorse Bioanalyzer. Sensitivity to cytostatics was measured using MTS assay and/or absolute count and flow cytometry. Mitochondrial membrane potential was determined as TMRE fluorescence.

Results

Using cell lines and primary patient samples we characterized the basal metabolic state of cells derived from different leukemia subtypes and assessed their sensitivity to cytostatic drugs. We found that leukemia cells cluster into distinct groups according to their metabolic profile. Lymphoid leukemia cell lines and patients sensitive to L-asparaginase clustered into the low glycolytic cluster. While lymphoid leukemia cells with lower sensitivity to L-asparaginase together with resistant normal mononuclear blood cells gathered into the high glycolytic cluster. Furthermore, we observed a correlation of specific metabolic parameters with the sensitivity to L-asparaginase. Greater ATP-linked respiration and lower basal mitochondrial membrane potential in cells significantly correlated with higher sensitivity to L-asparaginase. No such correlation was found in the other cytostatic drugs tested by us.

Conclusions

These data support that cell metabolism plays a prominent role in the treatment effect of L-asparaginase. Based on these findings, leukemia patients with lower sensitivity to L-asparaginase with no specific genetic characterization could be identified by their metabolic profile.

Additional file 1: Supplementary Table S1. Genetic characterization of leukemia cell lines.

Additional file 2: Supplementary Table S2. List of primary antibodies.

Additional file 3: Supplementary Figure S1. Absolute values of metabolic parameters measured in 19 leukemia cell lines. (A–D) Parameters calculated from glycolytic function. (E–H) Parameters calculated from mitochondrial function. (I) OCR/ECAR ratio calculated after glucose injection during the Glycolysis stress test measurement. (J) FAO rate. AML is presented as black graphs, B-ALL as white and T-ALL as gray graphs. (K) Levels of signaling proteins in the leukemia cell lines were measured by immunoblotting. β-actin was used as a loading control. Relative quantification (normalized to β-actin) was calculated in ImageJ. * p < 0.05, ** p < 0.01, *** p < 0.001. The immunoblot is a representative result of three independent experiments.

Additional file 4: Supplementary Figure S2. Effect of OXPHOS inhibitors on the growth and mitochondrial respiration of leukemia cell lines. (A) The effect of Oligomycin A (20 nM, 200 nM, 2 μM) on the growth and on the course of mitochondrial respiration of NALM-6 cells. (B) The effect of Antimycin A (10 ng/ml, 100 ng/ml and 1 μg/ml) on the growth and the course of mitochondrial respiration of NALM-6 cells. Cells were counted 48 and 72 h after the treatment. Cell Mito Stress Test was performed after 24 h of treatment. Measurements were done in three biological replicates and the data are presented as mean ± SD.

Additional file 5: Supplementary Figure S3. Functional study on the correlation between ETC complex III activity and sensitivity to ASNase. Effect of Antimycin A (10 ng/ml) on the sensitivity of leukemia cell lines (NALM-6, MV4;11) to ASNase. Cells were pretreated with Antimycin A for 1 h or left untreated and then co-treated with ASNase for 48 h. Absolute cell counts were obtained from three independent experiments; data were normalized to untreated controls and are presented as mean ± SD. Measurements were done in three biological replicates and the data are presented as mean ± SD.

Additional file 6: Supplementary Figure S4. Cluster analysis of patient samples according mitochondrial respiration. Hierarchical cluster analysis of primary leukemia cells and healthy control samples based on parameters calculated from mitochondrial function. Type of leukemia and IC50 ASNase [IU/ml] are indicated for each patient. For more information, see Table 2.

Alena Pecinova and Natividad Alquezar-Artieda contributed equally to this work.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s12885-020-07020-y.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

ALL

acute lymphoblastic leukemia

BCP-ALL

ALL derived from B-lineage

T-ALL

ALL derived from T-lineage

AML

acute myeloid leukemia

CML

chronic myeloid leukemia

ASNase

L-asparaginase

FAO

fatty acid oxidation

VCR

vincristine

DNR

daunorubicin

OCR

oxygen consumption rate

ECAR

extracellular acidification rate

MMP

mitochondrial membrane potential

Background

Leukemia is the most common malignancy and the second most frequent general cause of childhood death. It is classified as acute lymphoid of the B- or T-lineage being the most prevalent type in children, and as acute myeloid. Although tremendous improvements have been made in the treatment of leukemia in the past few years, there is still a large proportion of patients who do not benefit from the available therapy. The overall survival of pediatric acute lymhoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients treated with the current chemotherapy regimens is above 80 and 70%, respectively [1, 2].

The standardized treatment protocols consist of the same repertoire of cytostatic drugs which have been used for the past decades. They differ in the drug dosage, the time of administration and in the drug combinations. State-of-the-art genomic techniques have enabled the identification of new genetic alterations, which could be targeted by novel compounds; however, genetic-based approaches have not fully revealed the direct cause of inter-individual differences in the sensitivity to cytostatic drugs [3‐6]. Therefore, understanding the mechanism of action and being able to predict the impaired effect of commonly administered drugs is crucial for improving patient outcomes.

We turned our attention to cellular metabolism which represents a limiting process in cell proliferation and survival. Recent data have indicated that a number of cytostatic drugs trigger metabolic reprogramming, which impairs their effects and, in the long run, could cause resistance. Our group previously described that leukemia cells treated with L-asparaginase (ASNase) reprogrammed their metabolism and increased fatty acid oxidation (FAO) together with autophagy in order to compensate for asparagine and glutamine depletion [7]. Pharmacological inhibition of FAO increased the sensitivity to ASNase in leukemia cells, which supported its pro-survival effect and its potential role in the mechanism of resistance. A similar phenomenon was described in chronic lymphoblastic leukemia, where the administration of dexamethasone led to the increase in FAO [8]. Since treatment can dramatically influence the metabolic setup, we assume that reciprocally, the metabolic predisposition of cancer cells could also interfere with their response to treatment.

Our aim was to investigate how the basal metabolic profile of leukemic cells interferes with the effectiveness of the compounds currently used for treatment. We focused on cytostatic drugs used in the treatment of childhood leukemia with an emphasis on ASNase. ASNase represents a crucial drug used in the treatment of ALL; it is also incorporated in the front-line treatment of adult leukemia [9, 10]. Unfortunately, the sensitivity to ASNase differs significantly among ALL patients as described by Ramarkers et al. [11]. A specific phenotypic subgroup of ALL derived from a T lymphoid lineage (T-ALL) was also shown to be more resistant to ASNase treatment [12, 13]. In the current study, we have determined the metabolic phenotype of different types of leukemia in order to better understand their differences, metabolic demands, and their connection with the selective sensitivity of ASNase.

Methods

Cell culture

Human B-cell precursor leukemia cell lines (BCP-ALL; TOM-1, HB11;19, RS4;11, UOC-B6, REH, SUP-B15, NALM6), T-cell leukemia cell lines (HPB-ALL, CCRF-CEM, JURKAT, MOLT-4), AML cell lines (MV4;11, KASUMI-1, NB-4, THP-1, MOLM-13) and cell lines derived from the blast crisis of chronic myeloid leukemia (CML), which manifest as AML (K-562, LAMA-84) and as ALL (BV-173), were used (Table S1). The HB11;19 cell line was kindly provided by Dr. Anthony Ford from the Institute of Cancer Research (London, UK), and the UOC-B6 cell line was provided by Dr. Ondrej Krejci (Massachusetts General Hospital, Boston) [14]. The rest of the cell lines were purchased from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). The cell lines were negative for mycoplasma contamination and cultivated in RPMI-1640 medium with GlutaMAX™ supplemented with 10% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) under controlled conditions (37 °C, 5% CO₂). The cultured cells were split every 2 to 3 days and maintained in exponential growth phase.

Patient samples

Bone marrow or peripheral blood samples from untreated children initially diagnosed with BCP-ALL, T-ALL or AML were collected from the Czech Pediatric Hematology Centers. The inclusion criteria were the percentage of blasts higher than 80% and high cellularity. Within 24 h after aspiration, without freezing, the mononuclear cells were isolated by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare, UK). All samples were obtained with the informed consent of the children’s parents or guardians. The study no. 201528848A was approved by the Ethical Committee of the University Hospital Motol, Prague, Czech Republic. Healthy controls were isolated from buffy coats (mixture of healthy individuals) using Ficoll-Paque PLUS (GE Healthcare, UK). To enrich samples for B-lymphocytes, buffy coat was pre-treated with RosetteSep™ Human B Cell Enrichment Cocktail (StemCell Technologies, USA) prior to Ficoll-Paque PLUS.

The isolated blasts were maintained in RPMI-1640 medium with GlutaMAX™ supplemented with 10% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL). For the MTS assay, insulin-transferrin-sodium selenite supplement was added to the culture media (Sigma-Aldrich, St Louis, MO, USA).

Mitochondrial FAO measurement

The cells were incubated for 4 h in culture medium containing 100 μM palmitic acid, 1 mM carnitine and 1.7 μCi [9,10(n)-³H] palmitic acid (GE Healthcare, UK) in the presence or absence of etomoxir (100 μM, Sigma-Aldrich, MO, USA). Medium was collected to analyze the amount of released ³H₂O that was formed during the cellular oxidation of [³H]-palmitate [15, 16]. The procedure was performed as described previously [7]. The measurement was performed in 3 independent experiments.

TMRE staining

The cells were incubated for 30 min in culture medium with or without 1 μM tetramethylrhodamine ethyl ester (TMRE; ThermoFisher Scientific Inc., MA, USA) and were then washed with PBS and analyzed on a flow cytometer according to the manufacturer’s instructions. The level of TMRE staining was expressed as the mean of the TMRE signal in the live cells. The measurement was performed in 3 independent experiments.

Cell survival and proliferation

To evaluate the cytotoxicity of ASNase, vincristine (VCR), and daunorubicin (DNR), MTS (dimethylthiazol carboxymethoxyphenyl sulfophenyl tetrazolium) assays were performed using a CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega Corporation, Wisconsin, USA) according to the manufacturer’s instructions and our previous publication [7]. Range of ASNase concentration used in the MTS assay was 0 - 4 IU/ml (5-fold dilutions), for VCR it was 0 - 50 nM (5-fold dilutions) and 0 - 3 μM (5-fold dilutions) for DNR. We seeded 1.2 × 10⁴ cells of leukemia cell lines and 1 × 10⁵-3 × 10⁵ patient cells. To evaluate the combined cytotoxicity of the 2 drugs, the number of live cells was determined by flow cytometry using DAPI (ThermoFisher Scientific Inc., MA, USA) and AccuCount Blank Particles (Spherotech Inc., IL, USA). The MTS assay was performed in at least 3 independent experiments. Cell counts were done in biological triplicates.

Seahorse extracellular flux analysis

Glycolytic and mitochondrial respiration parameters of the leukemia cell lines were measured on a Seahorse Analyzers XFe24 and XFp (Agilent Technologies, Inc., CA, USA) using a Glycolysis stress test and a Cell mito stress test. For the Glycolysis stress test, cells were seeded in XF Base medium, pH 7.4, and for the Cell mito stress test, cells were seeded in XF Assay medium, pH 7.4, supplemented with 10 mM glucose, 1 mM HEPES, pH 7.4, 1 mM pyruvate and 0.1% BSA. The cells were plated at a density of 300,000 cells/well in XFe24 or 40,000 cells/well in XFp tissue culture plates coated with CellTak (Corning GmbH, Wiesbaden, GER), according to the Agilent Seahorse protocol for seeding suspension cells.

The glycolytic and mitochondrial respiration parameters of the primary leukemia cells were measured on the Seahorse Analyzer XFp using the same tests and media as in the case of the cell lines. The primary cells were plated at a density of 500,000 cells/well in XFp tissue culture plates. The procedure was performed as described previously [17].

Final concentrations of the injected drugs were 10 mM glucose, 1 μM (for cell lines) or 2 μM (for primary cells) Oligomycin A and 100 mM 2-deoxy glucose (2-DG) in the Glycolysis stress test and 2 μM Oligomycin A, 1–4.5 μM FCCP (depending on the cell line) and 1 μM Rotenone combined with 1 μg/ml Antimycin A in the Cell mito stress test. All cell lines were measured at least in biological triplicates and 5 technical replicates on the Seahorse Analyzer.

Genomic DNA isolation and mtDNA quantification

Genomic DNA was isolated from leukemia cell lines using the QIAamp DNA Mini Kit (Qiagen GmbH, Germany) according to the manufacturer’s instructions. To quantify the mtDNA content, 2 genes were used as mitochondrial targets (16S rRNA and D-loop genes) and the GAPDH gene served as a nuclear target. Quantification was performed using real-time PCR as described elsewhere [18].

Electrophoresis and western blotting

Protein lysates were prepared as previously described [19]. The proteins (30 μg per well) were resolved by NuPAGE Novex 4–12% Bis-Tris Gels (ThermoFisher Scientific Inc., MA, USA) and transferred to a nitrocellulose membrane (Bio-Rad, CA, USA). The membrane was probed overnight with the primary antibodies listed in Table S2. The bound antibodies were detected with the appropriate secondary antibodies conjugated to horseradish peroxidase (Bio-Rad, CA, USA) and visualized using an enhanced chemiluminescence reagent and documented by Uvitec (Cambridge, UK).

Statistical analysis

Hierarchical clusters were generated in R using the Pheatmap package (distance measure: “Euclidean”, clustering method: “ward.D2”). Linearization method was used to calculate adjusted (bonferroni) p-values for Oligomycin A effect to ASNase, VCR and DNR sensitivity of leukemia cells (Fig. 3). Spearman rank correlations were calculated in R using the method “spearman”. P-values in Figure S1K were calculated using an unpaired, two-tailed, Mann-Whitney test in GraphPad Prism 6. Canonical Correlation analysis was done in R.

Results

Characterization of the basal metabolic state of leukemia cell lines

We used 19 human leukemia cell lines of different origin (8 BCP-ALL (ALL derived from B-lymphocytes; 1 BCP-ALL originated from a CML blast crisis), 4 T-ALL and 7 of myeloid origin (5 AML; 2 CML blast crisis manifesting as AML)); in all of them, we determined glycolytic function, mitochondrial respiration and FAO (Figure S1). Glycolytic and mitochondrial functions were measured on a Seahorse Analyzer XFe24 using Glycolysis stress test and Cell Mito stress test, respectively. This allowed us to measure and calculate different parameters within the glycolytic (basal acidification, glycolysis, glycolytic capacity, glycolytic reserve) and mitochondrial (basal respiration, ATP-linked respiration, maximal respiration, spare capacity) functions. FAO activity was measured as the oxidation of [³H]-palmitate.

Hierarchical clustering analysis (HCA) revealed that glycolysis and mitochondrial respiration, but not FAO, clustered leukemia cells separately according to the hematopoietic lineage from which they were derived (Fig. 1a, b, S1). Myeloid leukemia and T-ALL cell lines had overall higher values of glycolytic and cell respiration parameters and clustered together, while B-ALL cell lines with generally lower values gathered into the second cluster. Nevertheless, there were two exceptions. The HPB-ALL, a T-ALL cell line which clustered with the B-ALL and the NALM-6 and BV-173 B-ALL cell lines, which clustered together with the myeloid leukemia and T-ALL cell lines. In the case of NALM-6, this result was only achieved according to glycolytic function. Next, the OCR (oxygen consumption rate)/ECAR (extracellular acidification rate) ratio was calculated from the OCR and ECAR values, which were determined during the measurement of the glycolytic function after glucose addition (Figure S1). We plotted OCR against ECAR dividing leukemia cell lines according to their energy status. Cells preferentially oxidizing glucose in mitochondria have an aerobic status, while those utilizing glucose for fermentation to lactate have a glycolytic status. When both OCR and ECAR values are low, the cells are quiescent, whereas if both values are high, the cells are energetic, meaning they are very actively using both glycolysis and oxidative phosphorylation (OXPHOS, Fig. 1c).

Next, we tested which cellular processes could participate in a given metabolic state. The relative activity of major signalling pathways influencing basal metabolism was determined in 15 leukemia cell lines of different origin (6 B-ALL, 4 T-ALL, 5 AML; Figure S1K). The western blots were quantified by densitometry (normalized to β-Actin level). Importantly, we found higher levels of constitutively phosphorylated AKT (p-AKT) in all of the T-ALL cell lines when compared to the B-ALL cell lines (p = 0.0095). Furthermore, the levels of phosphorylated GSK-3β (glycogen synthase kinase 3 beta; p-GSK-3β) at Ser9 in the B-ALL cell lines were significantly lower compared to the levels in the AML cell lines (p = 0.0455) Activation of GSK-3β by dephosphorylation inhibits glycogen synthesis. We also detected elevated phospho-S6 (protein S6; p-S6), a downstream target of the PI3K/AKT/mTOR pathway, in the AML cell lines compared to the B-ALL cell lines (p = 0.0303). Moreover, we found significant difference in the levels of c-MYC (an activator of glycolysis) between the B-ALL and the T-ALL cell lines (p = 0.0190). We did not see any significant difference in the levels of p-AMPK (an AMP-activated protein kinase with a role in cellular energy homeostasis) among leukemia types.

Association of the metabolic profile of leukemia cells and their sensitivity to cytostatic drugs

Next, we investigated if there is a relationship between the metabolic phenotype of leukemic cells and the treatment sensitivity. First, we measured the sensitivity of all 19 leukemia cell lines to ASNase, Vincristine (VCR) and Daunorubicin (DNR). The last 2 drugs are included in the treatment of a broader spectrum of cancers. First, sensitivity to ASNase did not correlate with sensitivity to VCR and DNR, which demonstrated that the tested leukemia cell lines are not generally sensitive or resistant to cytostatic drugs. However, due to their intrinsic properties they respond independently to drugs with different mechanisms of action (Table 1a; Fig. 2a). We observed that myeloid cell lines are least sensitive to ASNase, followed by T-ALL cells, with B-ALL cell lines being the most sensitive ones (Table 1b).

Table 1

Sensitivity of leukemia cell lines to cytostatic drugs

A					B
Cell line	Type	IC50 ASNase [U/ml]	IC50 VCR [μM]	IC50 DNR [μM]	Type	Median			Mean ± SEM
HPB-ALL	T-ALL	0.000192	0.049900	0.111165		IC50 ASNase [IU/ml]	IC50 VCR [μM]	IC50 DNR [μM]	IC50 ASNase [IU/ml]	IC50 VCR [μM]	IC50 DNR [μM]
REH	B-ALL	0.000231	0.000420	0.007571	B-ALL	0.000677	0.001601	0.004953	0.1206 ± 0.0613	0.001437 ± 0.000376	0.007675 ± 0.001731
RS4;11	B-ALL	0.000378	0.002049	0.004953	T-ALL	0.3061	0.003056	0.03728	0.2677 ± 0.1099	0.014600 ± 0.011770	0.051480 ± 0.021210
SUP-B15	B-ALL	0.000549	0.000428	0.004655	AML	0.4385	0.001399	0.006661	0.4344 ± 0.0779	0.001615 ± 0.000562	0.014400 ± 0.006673
HB11;19	B-ALL	0.000677	0.002534	0.004509
TOM-1	B-ALL	0.158103	0.001601	0.003750
MOLT-4	T-ALL	0.175502	0.002784	0.052362
THP-1	AML	0.200475	0.001399	0.039269
NALM-6	B-ALL	0.328894	0.002578	0.013874
MV4–11	AML	0.336387	0.003011	0.017245
UOC-B6	B-ALL	0.355603	0.000450	0.014414
JURKAT	T-ALL	0.436766	0.002393	0.022205
KASUMI-1	AML	0.438479	0.002823	0.006661
CCRF-CEM	T-ALL	0.458528	0.003328	0.020190
MOLM-13	AML	0.557342	0.000418	0.002844
LAMA-84	CML in blast crisis (manifests as ALL)	0.611470	0.019001	0.109103
NB4	AML	0.639279	0.000424	0.005995
BV-173	CML in blast crisis (manifests as ALL)	0.654297	0.003051	0.023315
K-562	CML in blast crisis (manifests as AML)	0.715221	0.018563	0.048036

Next we asked if there was any relationship between the overall metabolic state of the leukemia cells (including all parameters measured) and their sensitivity to cytostatic drugs. For this purpose, we used Canonical Correlation analysis (CCA), which explores the relationship between 2 multivariate sets of variables. In our case, set 1 included all metabolic parameters, and set 2 consisted of the lineage origin and IC50s (Fig. 2b, c). Higher sensitivity to ASNase, preferentially presented in lymphoid leukemias, correlated most significantly with lower basal respiration, higher ATP-linked respiration and with a preference for oxidative (OCR/ECAR) over glycolytic metabolism (p = 0.0075, Fig. 2b). Higher sensitivity to DNR represented in AML correlated with lower basal respiration, higher ATP-linked respiration and lower FAO (p = 0.0295; Fig. 2c). Sensitivity to VCR did not correlate with any metabolic activity.

Functional study of the correlation between ATP synthase activity and the sensitivity to ASNase

For a functional confirmation of the results from CCA, we chose to inhibit ATP synthase activity in order to test the relationship between ATP-linked respiration and sensitivity to ASNase. First, we determined the optimal concentration of Oligomycin A (a specific inhibitor of ATP synthase) that effectively decreased the level of ATP, but at the same time did not completely inhibit cell proliferation. Thus, we counted live cells after 48 and 72 h of treatment with different concentrations of Oligomycin A (20 nM–2 μM). The results showed that 20 nM Oligomycin A inhibited the proliferation of leukemia cells to the same level as higher concentrations (Figure S2A). When measuring mitochondrial respiration, cells treated with 20 nM Oligomycin A had lower basal respiration than untreated cells. Moreover, this lowered respiration was not further reduced after 2 μM Oligomycin A injection, which means that ATP synthase was already inhibited (Figure S2A). OCR of untreated cells dropped dramatically after 2 μM Oligomycin A injection, reaching the level of 20 nM Oligomycin A-treated cells. Based on these data, we selected 20 nM Oligomycin A for further experiments.

Oligomycin A treatment was tested on 5 human leukemia cell lines of different origin (2 B-ALL, 2 T-ALL, 1 AML). Leukemia cells were pre-treated with 20 nM Oligomycin A for 1 h and then co-treated with different concentrations of ASNase or left untreated for 48 or 72 h. Then, live cells were counted using flow cytometry. The results showed that Oligomycin A pre-treatment increased the resistance of leukemia cells to ASNase compared to cells treated with ASNase alone (adjusted (bonferroni) p-value< 10^− 4; representative graphs of all treated cell lines are shown in Fig. 3a). This result suggests that cells with lower ATP synthase activity have a lower sensitivity to ASNase. The effect was evident in all tested cell lines. However, the cytostatic effect of VCR and DNR was not disturbed by Oligomycin A pre-treatment in the tested leukemia cell lines (Fig. 3b). Surprisingly, pre-treatment with 10 ng/ml of Antimycin A (inhibitor of ETC complex III) did not decrease the sensitivity of leukemia cells to ASNase compared to cells treated with ASNase alone (Figure S3). These results attest that the decreased sensitivity to ASNase in cells pre-treated with Oligomycin A is not due to reduced cell growth, since cells treated with both agents, i.e. Antimycin A (10 ng/ml) and Oligomycin A (20 nM), show similar growth reduction compared to non-treated cells (Figure S2).

Association of mitochondrial membrane potential with the sensitivity to ASNase

Basal mitochondrial membrane potential (MMP) was measured as TMRE fluorescence in 10 human leukemia cell lines of different origin (3 B-ALL, 4 T-ALL, 3 AML). Additionally, mitochondrial content was determined as the amount of mtDNA by real-time PCR. TMRE is an MMP-dependent dye and its fluorescence intensity is in proportion to both MMP and mitochondrial mass. TMRE fluorescence alone, or TMRE fluorescence normalized to mtDNA amount, clustered leukemia cell lines regardless of their origin (data not shown). On the other hand, in the tested leukemia cell lines, TMRE fluorescence significantly correlated (rho = 0.806; p-value = 0.00824) with sensitivity to ASNase (Fig. 4a). This means that cell lines with a higher TMRE fluorescence have in general a lower sensitivity to ASNase. Nevertheless, because TMRE fluorescence did not correlate with mtDNA quantity, it can be concluded that the observed TMRE changes are a representation of basal MMP in leukemia cells (Fig. 4b).

Characterization of the metabolic profile of leukemia patients

Although measuring the metabolic state of primary leukemia cells is quite challenging, we assessed the glycolytic and mitochondrial function of cells from 26 childhood leukemia patients (14 BCP-ALL, 7 T-ALL, 4 AML, 1 T/Myelo) and 2 healthy controls (B-cells, mononuclear cells)). We also determined the sensitivity of primary leukemia cells to ASNase by MTS assay (Table 2). HCA gathered patient samples according to their metabolic profile into 2 main clusters. The first cluster consisted, almost exclusively, of ALL patients (12/13). The second cluster included AML patients (3/4), a biphenotypic patient (1/1), healthy controls (2/2) and also ALL patients (9/21) (Fig. 5). Interestingly, ALL patients more sensitive to ASNase (11/13) clustered to the low glycolytic cluster, while patients less sensitive to ASNase (7/8) fell into the high glycolytic cluster. Mitochondrial respiration did not divide the ALL patients as did the glycolytic function (Figure S4).

Table 2

Characterization of leukemia patients

Patient	Type of leukemia	Genetic aberations	Age	Sex	Percentage of blasts during diagnosis	Peripheral blast count (×10⁹/l)	IC50 ASNase [IU/ml]
P01	pre-B ALL	KMT2A/MLLT3	1	F	91%	161.07	0.148802
P02	interT-ALL	none detected	6	F	81%	51.03	0.014910
P03	T-ALL	none detected	20	M	92%	NA	0.000291
P04	AML M4	CBFβ-MYH11	10	F	86%	122.12	0.114985
P05	AML M1	DEK-NUP214. FLT3-ITD	17	M	85%	28.82	0.000255
P06	pro-B ALL	ETV6-RUNX1	11	F	93%	8.18	0.040462
P07	AML M4	NPM1	17	F	83%	20.75	0.037307
P08	interT-ALL	none detected	8	F	94%	68.43	0.003352
P09	pre-B ALL	IKZF1del	1	M	89%	NA	0.284902
P10	interT-ALL	none detected	15	F	91%	NA	0.023467
P11	cALL	none detected	7	M	95%	40.28	0.125948
P12	cALL	ETV6-RUNX1	5	F	95%	4.18	0.117476
P13	cALL	ETV6-RUNX1	3	M	84%	4.20	0.001058
P14	cALL	ETV6-RUNX1	10	M	89%	3.39	0.105594
P15	cALL	ETV6-RUNX1	8	F	91%	56.60	0.000184
P16	cALL	hyperdiploid	16	F	93%	26.55	0.235677
P17	cALL (partial ProB)	none detected	8	F	97%	281.30	> 0.15
P18	T/Myelo	FLT3-ITD	9	M	88%	9.90	0.000242
P19	preT-ALL	none detected	12	F	75%	139.95	> 0.15
P20	cALL	ETV6-RUNX1	4	M	96%	31.97	0.000172
P21	pre-B ALL	none detected	2	M	91%	108.98	0.147981
P22	AML M5	KMT2A/MLLTA10	1	F	83%	366.28	0.000181
P23	interT-ALL	none detected	4	M	81%	93.64	0.104566
P24	cALL	ETV6-RUNX1	8	M	96%	NA	0.005477
P25	cALL	none detected	11	F	95%	6.042	> 0.15
P26	pro-B ALL	KMT2A/AFF1 (MLL-AF4)	< 1	F	92%	404.10	0.388752
H1	Healthy B-cells			NA			Resistant
H2	Healthy mononuclear cells			NA			Resistant

Discussion

The aim of this study was to elucidate if metabolic predisposition of leukemia cells (both cell lines and primary cells) influences their response to therapy. We wondered whether there is a basal metabolic profile that would predict which leukemia patients are sensitive or resistant to a given treatment. Since our previous work showed that ASNase affects the bioenergetics of leukemic cells, we were particularly interested in the link between the sensitivity to ASNase and the basal metabolic status of the cells as assessed before treatment. In addition to ASNase, we also tested the sensitivity to VCR and DNR, cytostatic drugs with a different mechanism of action, which are used in the treatment of a wide variety of cancers. We first examined the metabolic activity, including glycolysis, mitochondrial respiration and FAO in 19 cell lines. We performed HCA in order to cluster cell lines with a similar metabolic profile. Based on both glycolytic function and mitochondrial respiration, the cell lines were very similarly gathered into clusters. On the other hand, FAO clustered the cell lines differently. The first cluster, consisting of exclusively lymphoid leukemia cell lines, associated the cell lines with a lower glycolytic function and a lower mitochondrial respiration. The second cluster, grouped the cell lines with a higher glycolytic function and a higher mitochondrial respiration and contained all myeloid leukemia cell lines as well as some T-ALL cell lines. Next, aiming at the confirmation of this phenomenon in the primary samples, we assessed glycolytic function and mitochondrial respiration in leukemia cells isolated from ALL and AML patients and performed HCA. The first cluster which was divided according to glycolytic function consisted mostly of samples from ALL patients and the second cluster combined both, AML patients, ALL patients and healthy controls. After subsequent examination of the samples for their susceptibility to cytostatics, we found that ALLs from the high glycolytic cluster were less sensitive to ASNase treatment than their counterparts in the low glycolytic cluster. Moreover, a similar association was observed also in the tested cell lines. T-ALL lines from the high glycolytic cluster (and high respiration) were resistant to ASNase. Interestingly however, some AML patients were sensitive to ASNase to the same extent as sensitive ALL patients. This can be explained by the FAB classification according to which these AML patients fall into the M1, M4 or M5 subgroups. These morphological subgroups were shown to be more sensitive to ASNase treatment by in vitro testing [20]. This could be potentially clinically interesting since the incorporation of ASNase is still discussed in the treatment of AML.

In cell lines, IC50 of ASNase did not correlate with IC50 of VCR or DNR and also, the sensitivity to these cytostatics was not associated with any specific metabolic phenotype demonstrating that their effect was less influenced by the basal metabolic status of leukemia cells.

We have previously described specific signaling pathways that regulate bioenergetic processes after ASNase treatment [7]. We were therefore interested if a distinct metabolic profile of the leukemic cells would be associated with a different prerequisite activity of the signaling pathways. Indeed, we found a profound difference in p-AKT and c-MYC, the regulators of glycolysis [21, 22], between T- and B-ALL cells and decreased level of p-GSK3b in B-ALL cell lines. In the case of the AML cell lines, the proteins S6 and p-S6 were more expressed than in ALL cells.

Since we found an association between the metabolic predisposition and the consecutive response to ASNase treatment, we next asked which metabolic parameter correlates with IC50 of ASNase and therefore with the potential treatment efficacy. Statistical analysis based on CCA revealed that higher ATP-linked respiration, higher OCR/ECAR and lower basal respiration significantly correlated with increased sensitivity to ASNase. To functionally confirm this relationship we used Oligomycin A, a specific ATP synthase inhibitor. After its administration, we treated the cells with ASNase and examined the changes in cell survival and growth. We confirmed that cells with lower ATP synthase activity, i.e. lower ATP-linked respiration, are more resistant to ASNase. The sensitivity to VCR and DNR did not change, which corresponded with the results of the CCA. Reduced ATP synthase activity, in relation to a resistant phenotype, has been described in colorectal carcinoma cells and 5-fluorouracil [23]. Our assumption is that cells with less active TCA cycle followed by reduced ATP-linked respiration are less dependent on the supply of glucose or glutamine. Thus, these cells could better tolerate glutamine depletion and glucose uptake impairment, both of which are cytotoxic effects of ASNase.

Since Oligomycin A treatment leads to increased MMP [24], we examined the so-called basal MMP of cells using TMRE labeling. We have shown that higher MMP significantly correlates with higher resistance to ASNase. Since TMRE fluorescence measuring is a standardized cytometric method, it could be established as an additional diagnostic marker to help characterize the sensitivity of individual patients to ASNase.

Even though ASNase is a crucial component in the treatment of ALL, its precise administration is still being tested in some specific ALL prognostic-risk groups [25]. Moreover, its incorporation into the therapy of other cancer types is still under investigation [26‐29]. This is the first study describing the correlation between the sensitivity to ASNase and the metabolic profile of leukemia cells. Our results revealed that myeloid and lymphoid cells cluster together based on their glycolytic activity and mitochondrial respiration. Interestingly, both ALL cell lines and patients display different glycolytic activity which is associated with their sensitivity to ASNase. Further characterization of the metabolic state of the leukemic blasts, at the time of diagnosis, may help to identify patients with lower sensitivity to ASNase, individuals that are therefore more likely to fail the conventional therapy without any other detectable high-risk factors.

Conclusions

Our study provides novel findings on the role of cellular metabolism in the treatment response of leukemia patients. We have shown that metabolic phenotype in ALL cells can predict response to ASNase treatment in which less sensitive patients display high glycolytic action when compared to more sensitive patients with low glycolytic action. We also found correlation between ATP-linked respiration and basal MMP with the sensitivity to ASNase. These data support the role of cancer metabolism and open new potential ways in the diagnostic and treatment management of resistant leukemia patients.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s12885-020-07020-y.

Acknowledgements

We would like to thank the Czech and Slovak Pediatric Hematology Centers.

This study was approved by the University Hospital Motol Ethics Committee. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study.

Not applicable.

Competing interests

The authors declare no conflicts of interest.

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1: Supplementary Table S1. Genetic characterization of leukemia cell lines.

Additional file 2: Supplementary Table S2. List of primary antibodies.

Creutzig U, Zimmermann M, Bourquin J-P, Dworzak MN, Fleischhack G, Graf N, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from study AML-BFM 2004. Blood. 2013;122(1):37–43.CrossRef

Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014;32(3):174–84.CrossRef

Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758–64 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17344859. [cited 2016 Dec 22].CrossRef

Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, DaSilva A, et al. Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia. Cancer Cell. 2013;24(6):766-76.

Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature. 2018;553(7689):511–4 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29342136. [cited 2018 Apr 17].CrossRef

Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M, et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Med. 2013;19(3):368–71 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23377281. [cited 2018 Apr 17].CrossRef

Hermanova I, Arruabarrena-Aristorena A, Valis K, Nuskova H, Alberich-Jorda M, Fiser K, et al. Pharmacological inhibition of fatty-acid oxidation synergistically enhances the effect of l-asparaginase in childhood ALL cells. Leukemia. 2016;30(1):209–18 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26239197.CrossRef

Tung S, Shi Y, Wong K, Zhu F, Gorczynski R, Laister RC, et al. PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood. 2013;122(6):969–80 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23814018. [cited 2016 Dec 22].CrossRef

Liang J, Shi P, Guo X, Li J, He L, Wang Y, et al. A retrospective comparison of Escherichiaï¿½coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia. Oncol Lett. 2017;15(1):75–82 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29387211. [cited 2018 Apr 18].PubMedPubMedCentral

10.

Siegel SE, Stock W, Johnson RH, Advani A, Muffly L, Douer D, et al. Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia. JAMA Oncol. 2018; Available from: http://www.ncbi.nlm.nih.gov/pubmed/29450465. [cited 2018 Apr 18].

11.

Woerden NLR, Pieters R, Loonen AH, Hubeek I, Van Drunen E, Beverloo HB, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96(3):1094–9.

12.

Pieters R, den Boer ML, Durian M, Janka G, Schmiegelow K, Kaspers GJ, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants. Leukemia. 1998;12(9):1344–8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/9737681. [cited 2018 Apr 18].CrossRef

13.

Appel IM, Kazemier KM, Boos J, Lanvers C, Huijmans J, Veerman AJP, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22(9):1665–79 Available from: http://www.nature.com/articles/leu2008165. [cited 2018 Apr 18].CrossRef

14.

Kim DH, Moldwin RL, Vignon C, Bohlander SK, Suto Y, Giordano L, et al. TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines. Blood. 1996;88(3):785–94 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8704231. [cited 2018 Apr 18].CrossRef

15.

Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE, et al. A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med. 2012;18(9):1350–8 Available from: http://www.nature.com/doifinder/10.1038/nm.2882. [cited 2016 Dec 24].CrossRef

16.

Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim S-H, Mostoslavsky R, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1α. The EMBO J. 2007;26(7):1913–23 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17347648. [cited 2018 Apr 18].CrossRef

17.

Hlozková K, Starková J. Assessment of the Metabolic Profile of Primary Leukemia Cells. Journal of Visualized Experiments. 2018;(141). Available from: https://www.jove.com/video/58426/assessment-of-the-metabolic-profile-of-primary-leukemia-cells. [cited 2019 Jun 21].

18.

Pejznochová M, Tesarová M, Honzík T, Hansíková H, Magner M, Zeman J. The developmental changes in mitochondrial DNA content per cell in human cord blood leukocytes during gestation. Physiol Res. 2008;57(6):947–55 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18052680. [cited 2018 Apr 18].PubMed

19.

Hermanova I, Zaliova M, Trka J, Starkova J. Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase. Exp Hematol. 2012;40(8):657–65 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22542578. [cited 2018 Apr 19].CrossRef

20.

Okada S, Hongo T, Yamada S, Watanabe C, Fujii Y, Ohzeki T, et al. In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia. Br J Haematol. 2003;123(5):802–809. Available from: http://doi.wiley.com/10.1046/j.1365-2141.2003.04703.x. [cited 2020 Apr 16].

21.

Hung YP, Teragawa C, Kosaisawe N, Gillies TE, Pargett M, Minguet M, et al. Akt regulation of glycolysis mediates bioenergetic stability in epithelial cells. eLife. 2017;6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/29239720. [cited 2019 Oct 8].

22.

Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res. 2012;18(20):5546–53 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23071356. [cited 2019 Oct 8].CrossRef

23.

Shin Y-K, Yoo BC, Chang HJ, Jeon E, Hong S-H, Jung M-S, et al. Down-regulation of Mitochondrial F ₁ F ₀ -ATP Synthase in Human Colon Cancer Cells with Induced 5-Fluorouracil Resistance. Cancer Res. 2005;65(8):3162–70 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15833846. [cited 2019 Oct 8].CrossRef

24.

Perry SW, Norman JP, Barbieri J, Brown EB, Harris A. Gradient : a Practical Usage Guide. Biotechniques. 2011;50(2):98–115.CrossRef

25.

Rizzari C, Conter V, Starý J, Colombini A, Moericke A, Schrappe M. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25:S1–9.CrossRef

26.

Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther. 2006;5(11):2613–23 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17088436.CrossRef

27.

Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, et al. Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 2018;554(7692):378–81.CrossRef

28.

Panosyan EH, Wang Y, Xia P, Lee W-NP, Pak Y, Laks DR, et al. Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy against Brain Tumors. Mol Cancer Res. 2014;12(5):694–702 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24505127. [cited 2019 Jun 14].CrossRef

29.

Yu M, Henning R, Walker A, Kim G, Perroy A, Alessandro R, et al. L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. J Cell Mol Med. 2012;16(10):2369–78.CrossRef

Titel: Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase
verfasst von: Katerina Hlozkova
Alena Pecinova
Natividad Alquezar-Artieda
David Pajuelo-Reguera
Marketa Simcikova
Lenka Hovorkova
Katerina Rejlova
Marketa Zaliova
Tomas Mracek
Alexandra Kolenova
Jan Stary
Jan Trka
Julia Starkova
Publikationsdatum: 01.12.2020
Verlag: BioMed Central
Erschienen in: BMC Cancer / Ausgabe 1/2020
Elektronische ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-020-07020-y

Neu im Fachgebiet Onkologie

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Metabolic profile of leukemia cells influences treatment efficacy of L-asparaginase